GlassScriptPhysician profile
Samuel Piedad
NPI 1295732493
$154,200.34
in general payments reported to CMS, 2019-2025
62 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $3,848 · 2021: $2,889 · 2022: $13K · 2023: $36K · 2024: $66K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Honoraria: $28K · Travel and Lodging: $17K · Food and Beverage: $12K · Consulting Fee: $10K · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,800.00 |
| Honoraria | $27,810.00 |
| Travel and Lodging | $16,803.05 |
| Food and Beverage | $12,079.53 |
| Consulting Fee | $10,089.19 |
| Education | $315.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93,047.91 | 2019-2025 | Krystexxa, Tavneos, Evenity |
| Horizon Therapeutics Plc | $34,178.62 | 2022-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $8,786.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $6,904.61 | 2019-2025 | Jynarque, Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $1,490.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,217.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $948.17 | 2020-2025 | Acthar, Terlivaz |
| Daiichi Sankyo INC. | $613.91 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $556.93 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $555.58 | 2023-2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $545.81 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $491.06 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $477.63 | 2019-2025 | Eliquis, Cobenfy |
| Pfizer INC. | $454.56 | 2020-2025 | |
| Abbvie INC. | $451.34 | 2019-2024 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Piedad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.